Amnestix

About

Amnestix was an early-stage biotech company founded in 2006, that focused on novel therapeutics for improving memory deficits associated with a variety of human diseases. The company was founded on the discoveries of Dietrich Stephan, PhD, Director of the Neurogenomics Division and his associate, Matthew Huentelman, PhD, at the Translational Genomics Institute in Phoenix, Arizona, along with collaborators at the University of Zurich. Working with Amnestix Chief Executive Officer Karoly Nikolich, PhD, the company was developing small-molecule drugs for memory-related disorders. The sole funding for Amnestix was provided by Brain Trust Accelerator Fund I. Amnestix was successfully acquired in June 2008 by SYGNIS Pharma AG, a leading European biotechnology company.